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Summary: A congestive cardiomyopathy was diagnosed in a girl at the age 
of 4 weeks. In the weeks following she developed general muscle hypotonia nd 
plasma lactate increased to 8.5 mmol/L. Biochemical investigations of a muscle 
biopsy at the age of 3 months showed a deficiency in the oxidation of all 
substrates tested: pyruvate plus malate, 2-ketoglutarate and palmitate plus 
malate. After freezing and thawing of the homogenate and the addition of 
essential cofactors, the oxidation of the ketoacids normalized. The oxidation 
defect in the untreated homogenate can be explained by a deficiency in one of 
the cofactors (such as thiamine pyrophosphate, NAD + or CoASH), or by a 
defect in the oxidative phosphorylation. Treatment with thiamine and carnitine 
resulted in a decrease in blood lactate to normal evels and a dramatic linical 
improvement. Suspension of thiamine caused deterioration of her clinical 
condition and lactic acidaemia. The thiamine therapy was then continued. The 
girl is now 6 years old and in perfect health. 
INTRODUCTION 
Cardiomyopathy is often caused by a metabolic defect (Tripp, 1984; Kohlschfitter 
and Hausdorf, 1986; Lombes et al., 1987; Scholte et al., 1987b; Przyrembel, 1989). 
Without investigation fthe nature of the defect and specific treatment, the prognosis 
is bad. One-third of the patients die young and half of the survivors are severely 
handicapped (Tripp, 1984). 
CASE REPORT 
M.B., a girl born on 2 March 1984, the first child of unrelated parents, was admitted 
at the age of 3 weeks because of coughing fits, poor fluid intake, vomiting and loss 
of weight. Physical examination revealed a greyish skin colour, tachypnea, tachycardy 
and hepatomegaly. Routine laboratory investigation showed only a mild metabolic 
acidosis due to elevated plasma lactic acid. At the age of 4 weeks a congestive 
cardiomyopathy of unknown origin was diagnosed. She was treated with diuretics 
and tanoxin, and in the weeks following she developed general muscle hypotonia nd 
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increasing left ventricular hypertrophy and became unable to drink. 
A 24 h urine collected for metabolic investigation revealed no major abnormalities. 
Plasma lactic acid concentration was also normal at that time. However, in the 
subsequent weeks plasma lactic acid concentration increased to 8.5 mmol/L. Plasma 
free and esterified carnitine were in the control range. The excretion of free and 
esterified carnitine was also normal. After a 16 h overnight fast the blood glucose 
concentration was still 4.0 mmol/L. Ratios of free fatty acids/fl-hydroxybutyric ac d, 
free fatty acids/glucose and/%hydroxybutyric acid/glucose in plasma were normal. 
However, plasma lactate rose to 5.8 mmol/L after 12 h of fasting and subsequently 
decreased to 3.5 mmol/L during the next 4 h of fasting. A muscle biopsy from the 
quadriceps was taken under local analgesia t the age of 3 months by Prof. Dr H. 
F. M. Busch, who found no morphological or histochemical abnormalities. Because 
of her poor clinical condition and the possibility of a vitamin-responsive m tabolic 
disorder, treatment with L-carnitine (2 x 1 g/day), riboflavin (2 x 25 mg/day) and 
thiamine (2 x 25 rag/day) was given in addition to the diuretics and lanoxin while 
awaiting the results of the biochemical investigations of the muscle biopsy. This 
resulted in a dramatic improvement both clinically and biochemically. She was now 
able to drink by herself, the hypotonia disappeared and the blood lactate decreased to
normal levels (1.4 mmol/L). The biochemical investigations of the muscle homogenate 
revealed a low total carnitine content and decreased oxidation of pyruvate and 2- 
ketoglutarate, which normalized after freezing and thawing of the homogenate and 
the addition of the essential cofactors. Treatment with carnitine and thiamine was 
therefore continued, but riboflavin was stopped. Her clinical condition remained 
unchanged. 
When the girl was 6 months of age we attempted toevaluate the requirement for 
carnitine or thiamine. For a period of five weeks carnitine was lowered from 2 g to 
0.5 g/day. It was not completely suspended because of the danger of a temporary 
carnitine deficiency due to increased carnitine degradation i  patients with prolonged 
carnitine treatment (Scholte and de Jonge, 1985). During a second period of five 
weeks thiamine was discontinued and the carnitine treatment was maintained. Only 
during the second period did her condition worsen. The hypotonia gradually 
reappeared and she again became unable to drink by herself. Blood lactate 
concentration increased to 4 mmol/L. On reinstitution ofthe thiamine treatment the 
clinical symptoms and the lactic acidosis disappeared again. 
Now aged 6 years, she is a healthy girl with normal weight and length. Her 
echocardiogram shows a good contraction pattern and normal wall thickness of the 
left ventricle. The improvement in the ECG allowed cessation of diuretics at the age 
of 4 years. X-ray investigation still shows an enlarged heart, but with a normal ung 
vessel-filling pattern. 
METHODS 
Immediately after the biopsy a free homogenate was made consisting of 46 mg muscle 
in 1 ml of sucrose, heparin, EDTA medium (Bookelman et aI., 1978). 
The oxidation of 1 mmol/L 14C-pyruvate + 1 mmol/L 1-malate and of 1 mmol/L 
14C-2-ketoglutarate was studied in the same medium as that used for the study of 
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oxidative phosphorylation (Barth et al., 1983), but at 37°C, to enable comparison 
with the results obtained with the frozen muscle. 
The oxidation of U-14C palmitate to 14CO2 and ~4C-intermediates was studied as 
described by Scholte and colleagues (1987b), and the activity of malonyl-CoA 
decarboxylase with and without detergent was studied according to the method of 
Roodhooft and colleagues (1986). A second homogenate was made from frozen 
muscle (28 mg in 0.8 ml sucrose, HEPES, EDTA, albumin medium (Arts et al., 1987)) 
to study the oxidation of 1 mmol/L 1-~4C-2-ketoglutarate in the presence of thiamine 
pyrophosphate, CoASH, NAD +, carnitine, carnitine acetyttransferase andcytochrome 
c. The pyruvate oxidation was studied after 3 min inactivation by preincubation with 
Mg2+-ATP, followed by 5min activation with Ca 2+ and Mg 2+ (Arts et al., 1987). 
The other assays were performed in frozen batches of the first homogenate as 
described by Scholte and colleagues (1987a). 
RESULTS 
The results of the biochemical investigations of the muscle biopsy are summarized 
in Table 1. The control data for fresh muscle homogenate were calculated from the 
data obtained with freshly isolated mitochondria, with the assumption that the 
theoretical yield o1: mitochondria s 38 mg of mitochondrial protein per g of muscle 
(Scholte t al., 1987a). The control values for 1-14C pyruvate and 1-14C-2-ketoglutarate 
oxidation at 37°C were calculated from oxygen uptake rates with freshly isolated 
mitochondria at25°C (Scholte et al., 1987a), assuming that 5 and 2 ngat oxygen are 
consumed by the oxidation of 1 nmol pyruvate and 2-ketoglutarate, r spectively, and 
that the oxidation rates at 37°C are 2.2 times higher than at 25°C (Byrne and Trounce, 
1985). 
The oxidation of U-14C-palmitate was not measured infrozen-thawed homogenate 
because, after disruption of the mitochondria, the reaction is no longer linear with 
respect o time and enzyme concentration. I  fresh homogenate he rate of oxidation 
of pyruvate, 2-ketoglutarate and palmitate was much lower than in controls, while 
the activity of the mitochondrial marker enzyme matonyl-CoA decarboxytase 
measured in the presence of detergent was entirely normal. The frozen-thawed 
homogenate showed normal ketoacid oxidation rates after the addition of the essential 
cofactors thiamine pyrophosphate, CoASH and NAD+. 
The activities of the complexes of the mitochondrial respiratory chain, the muscle 
marker creatine kinase and the protein content were in the control range. Total 
carnitine was decreased. 
DISCUSSION 
Assays were performed inmuscle homogenates because the amount of tissue biopsied 
was too small to allow the isolation of a sufficient amount of mitochondria for 
reliable functional studies. 
In the fresh homogenate, the :patient showed a deficiency in the oxidation of all 
substrates tested: pyruvate, 2-ketoglutarate and palmitate. After freezing and thawing 
and addition of essential cofactors (thiamine pyrophosphate, CoASH, NAD ÷) and 
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Table 1 Oxidation of pyruvate and 2-ketoglutarate in fresh and frozen-thawed skeletal muscle 
homogenate compared with other mitochondrial activities, creatine kinase, protein and carnitine. 
The data for the patient are of the same muscle, biopsied before treatment. The enzyme activities 
are expressed as indicated amount of substrate converted min- 1 g wet muscle- 1. The control 
values for the fresh homogenates were calculated from experiments with freshly isolated 
mitochondria s indicated in the text. The mean value is given with the range in brackets. 
Patient Controls n 
Fresh homogenates 
1-14C-pyruvate oxidation (nmol pyruvate) 88 
1-~4C-2-ketoglutarate oxidation (nmol 2-ketoglutarate) 78 
U-14C-pafmitate oxidation (nmol palmitate) 
+ 1 mmol/L KCN + 0.1 mmol/L CoASH 1.5 8.7 (5.7-13.7) 12 
+ 0.5 mmot/L L-carnitine + 0.1 mmol/1 CoASH 4.4 66 (42-95) 14 
+ 5 mmol/L L-carnitine + t mmol/L CoASH 4.5 73 (43 86) 9 
Malonyl-CoA decarboxylase (nmot malonyt-CoA) 4.7 4.9 (0.0-31) 9 
+ detergent 38 55 (33 116) 9 
1538 (836 2408) 22 
2424 (1714-2668) 12 
Frozen-thawed homogenates 
1-14C-pyruvate oxidation (nmol pyruvate) 823 866 (520-1276) 9 
1-14C-2-ketoglutarate oxidation (nmol 2-ketoglutarate) 1t69 1091 (505 2301) 30 
Rotenone-sensitive NADH-oxidase (/zmol NADH) 2.2 3.2 (1.6-4.2) 10 
Succinate dehydrogenase (nmol INT +) 563 723 (t87-1640) 58 
Antimycin-sensitive succinate-cytochrome c r ductase 
(#tool cytochrome c) 2.6 4.0 (1.6 8.1) 21 
Cytochrome e oxidase (rate constant k) 57 90 (45-161) 26 
Creatine kinase (#mol creatine) 177 307 (83-430) 50 
Protein (mg/g wet weight) 89 174 (77-263) 53 
Total carnitine (/~mol/g wet weight) 1.3 4.0 (2.6-5.7) 59 
n = number of controls INT + = p-iodonitrotetrazolium 
cytochrome c, the activities of the oxoacid dehydrogenases became normal. The 
apparent deficiency could be caused by a deficiency in one of the cofactors or a defect 
at the level of thiamine, and because of the carnitine deficiency in oxidative 
phosphorylation. Other mitochondrial marker enzymes, including segrfients of the 
respiratory chain, showed the same activity as in controls. The integrity of the 
mitochondrial inner membranes, measured by the stimulation of the matrix enzyme 
malonyl-CoA decarboxylase by detergent, was also normal. 
One of the explanations for these findings, a defect at he level of thiamine, and 
the observed carnitine deficiency, suggested a biochemical basis for a trial of treatment 
with these substances. The blood lactate normalized within four weeks. The therapeutic 
regimen appeared to be justified by the dramatic improvement in the patient's 
condition and the disappearance of the lactic acidosis. The early onset of the disease, 
and the fact that lactic acidosis reappeared after suspension of the treatment, excludes 
beriberi and we therefore suspect hat the patient has a defective incorporation of 
thiamine. The carnitine deficiency in the muscle is likely to be a consequence of the 
defect in the Krebs cycle. Acetyl-CoA is no longer oxidized and one would expect 
increased acetylcarnitine to be excreted with the urine, resulting in depletion of tissue 
carnitine. The normal level of urinary acetylcarnitine could support this theory, in 
d. lnher. Metab. Dis. 14 (1991) 
Thiamine Responsive Cardiomyopathy 79 
view of the much lower muscle carnitine pool in the patient. The reduced beta 
oxidation in the muscle homogenate also remains to be explained. Since it is measured 
in the presence of the required factors, including L-malate, the decrease cannot be 
caused by the defect in 2-ketoglutarate oxidation. The decrease in mitochondrial nd 
peroxisomal (measured in the presence of KCN) palmitate oxidation is probably 
caused by dilution of the labelled palmitate by long-chain fatty acids, released from 
the triacylglycerols by lipoprotein lipase, stimulated by heparin, which was present 
in the homogenization medium. 
Although the precise metabolic defect has still to be assessed, we conclude that 
our patient has a defect in thiamine metabolism which is responsive to thiamine. 
This implies that carnitine can be tapered off without clinical consequences. We 
advocate metabolic investigation of patients with cardiomyopathy, followed by 
rational treatment based on the biochemical lesion(s) encountered in skeletal muscle 
biopsy. 
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